Elamipretide for Fatigue: Trial Results

The largest comparison

Elamipretide is often discussed as a mitochondrial treatment, but that description does not identify the patients for whom an outcome was demonstrated. MMPOWER-3 tested genetically confirmed primary mitochondrial myopathy, a group of disorders affecting mitochondrial energy production. Its 218 participants were assigned equally to elamipretide or placebo, and the investigators assessed walking distance and fatigue after 24 weeks ^[1].

Neither primary outcome improved significantly. The difference in six-minute walking distance was -3.2 meters, with a confidence interval from -18.7 to 12.3 meters and p = 0.69. The fatigue comparison also missed statistical significance, p = 0.37. Those results do not establish a meaningful benefit concealed behind a positive trial headline; the trial itself concluded that the two principal outcomes did not improve ^[1].

The Barth syndrome distinction

TAZPOWER studied Barth syndrome, a rare genetic condition involving cardiolipin, rather than the broader mitochondrial myopathy population. Twelve participants entered its randomized crossover phase, which compared treatment and placebo within the same participants. Neither the walking-distance endpoint nor the Barth syndrome symptom endpoint was met during that blinded comparison ^[2].

Ten participants continued into an open-label extension, and eight reached 36 weeks. At that point, walking distance had increased by 95.9 meters and the symptom score had improved by 2.1 points. These observations deserve reporting, but they occurred after the placebo comparison had ended. Participants and investigators knew the treatment, and the later result describes a smaller continuing group ^[2].

What the comparison supports

The two studies cannot be joined into a general claim that mitochondrial peptides restore energy. They involve different diseases, different follow-up periods and different control conditions. A positive change during an extension does not reverse a negative randomized comparison in another population. Likewise, the negative myopathy trial does not prove that every possible use in Barth syndrome is ineffective ^{[1, 2]}.

Tolerability is a separate outcome. MMPOWER-3 reported that most adverse events were mild or moderate and described treatment as well tolerated. That finding concerns the product, participants and duration actually studied; it does not establish the quality of material sold under the SS-31 name or demonstrate long-term safety in healthy people ^[1].

The practical reading

For fatigue claims, the closest large controlled study is the negative MMPOWER-3 trial, not the favorable extension alone. A claim about healthy aging or ordinary tiredness requires evidence in those populations; neither of these trials enrolled them. Mechanistic similarity is a reason to investigate, rather than a substitute for that investigation ^{[1, 2]}.

The elamipretide monograph separates the product label from the wider research literature. The mitochondrial class also includes molecules with different evidence and regulatory positions, so a shared class label should never be read as interchangeable clinical support.

Elsewhere in this index